Activating autoantibodies against the AT1-receptor in vascular disease

Ralf Dechend*, Duska Dragun, Florian Herse, Gabriele Riemekasten, Kai Schulze-Forster, Dominik N. Müller, Harald Heidecke

*Korrespondierende/r Autor/-in für diese Arbeit
2 Zitate (Scopus)


Activating autoantibodies to the angiotensin II type I receptor (AT1-AA) have been described in different vascular diseases: preeclampsia, non HLA-mediated transplantat rejection and systemic sclerosis. All three diseases are characterised by severe obliterative, inflammatory vasculopathy with a prominent autoimmune background. AT1-AA were described 12 years ago in preeclampsia. Preeclampsia is a common, pregnancy- induced disorder, consisting of hypertension and proteinuria in the last trimester. The condition is one of the leading causes for maternal and perinatal morbidity and mortality. An observation of a patient with transplant rejection without HLA antibodies and a preeclampsia in her medical history, let to the discovery of AT1-AA in these patients. Until then we relied on a subjective, time consuming bioassay to detect AT1-AA. The establishment and validation of a cell-based ELISA facilitated research on AT1-AA immensely. Recently, AT1-AA were found in patients with systemic sclerosis.

ZeitschriftTransplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft
Seiten (von - bis)20-26
PublikationsstatusVeröffentlicht - 2012

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)


Untersuchen Sie die Forschungsthemen von „Activating autoantibodies against the AT1-receptor in vascular disease“. Zusammen bilden sie einen einzigartigen Fingerprint.